Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer
Wolf Köster(Kliniken Essen-Mitte), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Andrea Heider(Klinikum Leverkusen), Jürgen R. Fischer, N. Niederle(Klinikum Leverkusen), Jens Albrecht Koch(Kliniken Essen-Mitte), Georgios Stamatis(Ruhrlandklinik), H. Wilke(Kliniken Essen-Mitte)
Cited by 26
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis
|Genes & Development|2009|351
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2020|202
Sch9 regulates ribosome biogenesis via Stb3, Dot6 and Tod6 and the histone deacetylase complex RPD3L
|The EMBO Journal|2011|179